Skip to content
Sign in

AIM · AMEX

AIM ImmunoTech (AIM) Stock Price & Fundamentals

$873.20−0.23%−$2.04End-of-day price as of Oct 9, 2026

AIM ImmunoTech (AIM) closed at $873.20 on Oct 9, 2026, down 0.23% from the previous close of $875.24.

Share price, past year

1Y +34.02%

52-week range $651.54 – $889.72. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$873.20
Sep 30, 2026$877.02
Aug 31, 2026$808.69
Jul 31, 2026$799.00
Jun 30, 2026$740.51
May 29, 2026$796.04
Apr 30, 2026$780.57
Mar 31, 2026$748.51
Feb 27, 2026$781.20
Jan 30, 2026$796.42
Dec 31, 2025$782.97
Nov 28, 2025$748.00
Oct 31, 2025$695.14

Key statistics

Market cap
$25.31B
P/E (TTM)
—
EPS (TTM)
−$6.01
Revenue (TTM)
$95.00K
Net income (TTM)
−$14.27M
Shares outstanding
29M
Dividend yield
—
52-week range
$651.54 – $889.72

AIM ImmunoTech's market cap is $25.31B, based on a share price of $873.20 and 29M shares outstanding as of Jun 30, 2026.

Financials

AIM ImmunoTech reported revenue of $88.00K for fiscal 2025, down 48.24% from fiscal 2024.

AIM ImmunoTech reported a net loss of $13.96M in fiscal 2025.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
AIM ImmunoTech annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$88.00K−48.2%−$13.96M−15,861.4%−$8.62—
FY2024ended Dec 31, 2024$170.00K−15.8%−$17.32M−10,188.2%−$30.92−$14.91M
FY2023ended Dec 31, 2023$202.00K+43.3%−$28.96M−14,337.6%−$0.60—
FY2022ended Dec 31, 2022$141.00K+4.4%−$19.45M−13,790.8%−$0.40−$16.19M
FY2021ended Dec 31, 2021$135.00K−17.2%−$19.13M−14,168.2%−$0.40−$14.01M
FY2020ended Dec 31, 2020$163.00K+16.4%−$14.40M−8,834.4%−$0.45−$10.39M
FY2019ended Dec 31, 2019$140.00K−61.9%−$9.40M−6,717.1%−$2.58−$9.14M
FY2018ended Dec 31, 2018$367.00K−16.0%−$9.83M−2,677.7%−$9.77−$10.69M
FY2017ended Dec 31, 2017$437.00K+375.0%−$8.26M−1,889.9%−$0.29−$7.96M
FY2016ended Dec 31, 2016$92.00K—−$7.50M−8,154.4%−$0.34−$7.54M
AIM ImmunoTech quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$26.00K−$3.79M−$0.43
Q1 FY2026ended Mar 31, 2026$22.00K−$3.02M−$0.69
Q4 FY2025ended Dec 31, 2025$21.00K−$4.18M−$6.46
Q3 FY2025ended Sep 30, 2025$26.00K−$3.28M$1.57
Q2 FY2025ended Jun 30, 2025$25.00K−$2.79M−$3.68
Q1 FY2025ended Mar 31, 2025$16.00K−$3.71M−$0.05
Q4 FY2024ended Dec 31, 2024$45.00K−$5.97M−$21.80
Q3 FY2024ended Sep 30, 2024$35.00K−$3.70M−$6.00

Company profile

Name
AIM ImmunoTech Inc.
Ticker
AIM
Exchange
AMEX
Industry (SEC SIC)
Biological Products, (No Diagnostic Substances)
Headquarters
2117 Sw Highway 484, Ocala, FL 32801
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0000946644

Recent SEC filings

Frequently asked questions

What is AIM ImmunoTech's stock price?

AIM ImmunoTech (AIM) closed at $873.20 on Oct 9, 2026, down 0.23% from the previous close of $875.24.

What is AIM ImmunoTech's market cap?

AIM ImmunoTech's market cap is $25.31B, based on a share price of $873.20 and 29M shares outstanding as of Jun 30, 2026.

How much revenue does AIM ImmunoTech make?

AIM ImmunoTech reported revenue of $88.00K for fiscal 2025, down 48.24% from fiscal 2024.

Does AIM ImmunoTech pay a dividend?

AIM ImmunoTech's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from AIM ImmunoTech Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures